Physiologic tailoring of treatment in resistant hypertension
- PMID: 21532778
- PMCID: PMC2892077
- DOI: 10.2174/157340310791162695
Physiologic tailoring of treatment in resistant hypertension
Abstract
Resistant hypertension is a major opportunity for prevention of cardiovascular disease. Despite widespread dissemination of consensus guidelines, most patients are uncontrolled with approaches that assume that all patients are the same. Causes of resistant hypertension include 1) non-compliance 2) consumption of substances that aggravate hypertension (such as salt, alcohol, nonsteroidal anti-inflammatory drugs, licorice, decongestants) and 3) secondary hypertension. Selecting the appropriate therapy for a patient depends on finding the cause of the hypertension. Once rare causes have been eliminated (such as pheochromocytoma, licorice, adult coarctation of the aorta), the cause will usually be found by intelligent interpretation (in the light of medications then being taken) of plasma renin and aldosterone.If stimulated renin is low and the aldosterone is high, the problem is primary aldosteronism, and the best treatment is usually aldosterone antagonists (spironolactone or eplerenone; high-dose amiloride for men where eplerenone is not available). If the renin is high, with secondary hyperaldosteronism, the best treatment is angiotensin receptor blockers or aliskiren. If the renin and aldosterone are both low the problem is over-activity of renal sodium channels and the treatment is amiloride. This approach is particularly important in patients of African origin, who are more likely to have low-renin hypertension.
Keywords: African-American; Resistant hypertension; Stroke belt.; amiloride; primary hyperaldosteronism; renal sodium channel; renin.
Figures
Similar articles
-
Controlling resistant hypertension.Stroke Vasc Neurol. 2018 Feb 24;3(2):69-75. doi: 10.1136/svn-2017-000138. eCollection 2018 Jun. Stroke Vasc Neurol. 2018. PMID: 30022799 Free PMC article. Review.
-
The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.Circulation. 2007 Jul 17;116(3):268-75. doi: 10.1161/CIRCULATIONAHA.107.690396. Epub 2007 Jul 2. Circulation. 2007. PMID: 17606839 Clinical Trial.
-
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Lancet Diabetes Endocrinol. 2018. PMID: 29655877 Free PMC article.
-
Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.Clin Endocrinol (Oxf). 2002 Oct;57(4):457-65. doi: 10.1046/j.1365-2265.2002.01613.x. Clin Endocrinol (Oxf). 2002. PMID: 12354127
-
Resistant hypertension and aldosteronism.Curr Hypertens Rep. 2007 Nov;9(5):353-9. doi: 10.1007/s11906-007-0066-7. Curr Hypertens Rep. 2007. PMID: 18177580 Review.
Cited by
-
Licorice Root Associated With Intracranial Hemorrhagic Stroke and Cerebral Microbleeds.Neurohospitalist. 2019 Jul;9(3):169-171. doi: 10.1177/1941874418805332. Epub 2018 Oct 15. Neurohospitalist. 2019. PMID: 31244975 Free PMC article.
-
Genetics of resistant hypertension: a novel pharmacogenomics phenotype.Curr Hypertens Rep. 2015 Sep;17(9):583. doi: 10.1007/s11906-015-0583-8. Curr Hypertens Rep. 2015. PMID: 26198781 Free PMC article. Review.
-
Intensive risk factor control in stroke prevention.F1000Prime Rep. 2013 Oct 1;5:42. doi: 10.12703/P5-42. F1000Prime Rep. 2013. PMID: 24167723 Free PMC article. Review.
-
Secondary stroke prevention.Nat Rev Neurol. 2010 Sep;6(9):477-86. doi: 10.1038/nrneurol.2010.114. Epub 2010 Aug 10. Nat Rev Neurol. 2010. PMID: 20697424 Review.
References
-
- Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment and control of hypertension in Canada. Am J Hypertens. 1997;10(1097):1102. - PubMed
-
- Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–7. - PubMed
-
- Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112(23):3562–8. - PubMed
LinkOut - more resources
Full Text Sources
